The defendants
The defendants
As already noted, the first to sixth defendants are entities in the SoftBank Group, comprising the first defendant (“SBG”), its subsidiaries, affiliates and investment vehicles. At all relevant times, SBG was, through the second to sixth defendants, a significant indirect investor in and lender to both the Katerra Group and the Greensill Group.
SBG is a strategic investment holding company publicly listed on the Tokyo Stock Exchange.
SBG’s stated strategy is “to form a diverse group of companies with outstanding technologies and business models in specific fields”, and to encourage those companies “to form synergies to evolve and grow together”. SBG’s stated aim is to do this through investing in target companies through dedicated special purpose funds and vehicles, which include the second to sixth defendants (together, “the Vision Fund defendants”). The holdings in SBG’s investment portfolio include Vision Fund I (“SVF1”) and Vision Fund II (“SVF2”) (together “the Vision Funds”).
SVF1 consists of the fifth defendant, SoftBank Vision Fund LP, and its alternative investment vehicles. SVF2 consists of the sixth defendant, SoftBank Vision Fund II-2 LP, and its alternative investment vehicles. SBG was a limited partner in SVF1 along with other limited partners. SBG was the sole limited partner in SVF2. SBG was entitled to a capital return and distribution of gains from SVF1 after the payment out of preferred equity limited partners, and to unrestricted capital return and distribution of gains from SVF2. The general partners of SVF1 and SVF2 (respectively, SVF GP (Jersey) Limited and SVF II GP (Jersey) Limited) were wholly-owned subsidiaries of SBG.
The second to fourth defendants are companies incorporated in the Cayman Islands through which the Vision Funds make investments. Specifically: the second defendant, SVF II Abode (Cayman) Limited (“SVF II Abode”) is a company through which SVF2 makes investments; the third defendant, SVF Abode (Cayman) Limited (“SVF Abode”) is a company through which SVF1 makes investments; the fourth defendant, SVF Habitat (Cayman) Limited (“SVF Habitat”) is a company through which SVF1 makes investments.
SoftBank Investment Advisers (UK) Limited (“SBIA UK”) acted during the relevant times as manager of the Vision Funds. SBIA UK was entitled to management and performance fees from both of the Vision Funds. SB Investment Advisers (US) Inc. (“SBIA US”) provided investment sub-advisory services to SBIA UK. The two companies are collectively referred to below as “SBIA”.
During the relevant period, (i) Mr Masayoshi Son was SBG’s largest shareholder and also its Chairman and CEO. He continues to occupy those roles. (ii) Mr Rajeev Misra sat on the Board of SBG and acted as an Executive Vice President, and was CEO of SBIA and the Vision Funds. (iii) Mr Son and Mr Misra were identified on the Vision Funds’ dedicated websites as constituting their “Leadership”. (iv) Mr Saleh Romeih was a Managing Partner at SBIA UK. (v) Mr Son, Mr Romeih and Mr Misra together comprised the SBIA Investment Committee which was required to approve any investments by the Vision Funds. (vi) Mr Colin Fan was a Managing Partner of SBIA reporting to Mr Misra. (vii) Mr Tommy Cheung was the lead Partner at SBIA US for fintech and financial services orientated investments. He reported to Mr Fan. (viiii) Mr Tom Daula was SBIA’s Chief Risk Officer. (ix) Ms Hayley Chan was a Vice President working in the SBIA fintech investment team. She reported to Mr Cheung.
Mr Son remains SBG’s largest shareholder, Chairman and CEO. Mr Misra left his role as CEO of SBIA and the Vision Funds in November 2024 but remains employed by SB Investment Advisers (AD) Limited as a Senior Adviser to the Vision Funds.
The relevant entities in the SoftBank Group at the relevant times are shown in the following chart:

- Heading
- INTRODUCTION
- The claimants
- The defendants
- The Greensill Group and supply chain funding
- The SCF Funds
- The securitised funding arrangements
- The SoftBank Defendants’ relationships with the Greensill Group
- The Credit Enhancement Programme
- The Katerra Group companies
- The SoftBank Defendants’ investments in the Katerra Group companies
- 2019 discussions about revisions to the Credit Enhancement Programme
- The Fairymead Note Programme
- December 2019: further discussions about the CEP
- The issue of notes under the Fairymead Note Programme
- 2020: Financial stress in the Katerra Group
- SVF1 invested further in Katerra
- Katerra identified improper revenue recognition
- Appointment of new management and restructuring advisors
- Developments concerning the Greensill Group in 2020
- CSAM reduced concentration limits on Greensill Group investments
- GCPL planned a capital raise and Initial Public Offering
- Drafts of the $440 million CLN and the Omnibus Deed
- The 10 November 2020 agreements
- The $440m CLN
- The Omnibus Deed
- The SBIA Undertaking
- Use of the $440 million proceeds of the CLN
- Further developments in November 2020 concerning the Katerra Group
- SVF1’s bridge loan to the Katerra Group
- SVF1’s, SVF2’s and the Greensill Group’s approvals following the withdrawal of the New Money Consortium
- Documenting the agreements
- Signing of the CEA and TA and placing them in escrow
- Further agreements executed in December 2020
- The CEA
- The TA
- Further investments in Katerra Cayman by SVF1
- The Preferred Share Purchase Agreement
- The SVF Habitat Share Subscription
- The Vision Funds’ stake in the Katerra Group
- November to December 2020: developments concerning the Fairymead Note Programme
- December 2020 – March 2021: Financial position of the Greensill Group
- Discussions between Greensill and CSAM in December 2020 about exposure limits
- The 31 Dec/14 Jan Fairymead Trade – “the Secondary Trade”
- Publicity about the restructuring of the Katerra Group’s debts
- The cancellation of the Secondary Trade
- March – June 2021: Default on the Fairymead Notes and bankruptcy of the Greensill Group and Katerra Group
- WITNESSES
- FINDINGS ON CONTESTED FACTUAL AND EXPERT ISSUES
- SECTION 423 OF THE INSOLVENCY ACT 1986
- DETERMINATION OF THE ELEMENTS OF THE CLAIM
- Conclusions
![FL-2022-000014 - [2025] EWHC 2631 (Ch)](https://backend.juristeca.com/files/emisores/logo_O3rEzCI.png)